Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

33.53 -0.99 (-2.85%)

Streaming Delayed Price Updated: 11:29 AM EDT, Sep 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,359,195
Open	34.64
Bid (Size)	33.53 (200)
Ask (Size)	33.55 (200)
Prev. Close	34.52
Today's Range	33.45 - 35.04
52wk Range	11.94 - 37.97
Shares Outstanding	692,072,184
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately ↗

August 28, 2026

Roivant Sciences (NASDAQ:ROIV) said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered...

Via MarketBeat

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

August 27, 2026

From Roivant Sciences

Via GlobeNewswire

Performance

YTD	+52.9%	+52.9%
1 Month	+0.6%	+0.6%
3 Month	+18.7%	+18.7%
6 Month	+20.4%	+20.4%
1 Year	+170.7%	+170.7%

More News

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

August 27, 2026

From Roivant Sciences

Via GlobeNewswire

JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis

August 26, 2026

From Roivant Sciences

Via GlobeNewswire

ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings ↗

May 14, 2026

Via Chartmill

Roivant Sciences Q1 Earnings Call Highlights ↗

August 07, 2026

Via MarketBeat

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

August 06, 2026

From Roivant Sciences

Via GlobeNewswire

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

August 06, 2026

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

July 23, 2026

From Roivant Sciences

Via GlobeNewswire

Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? ↗

July 07, 2026

Via The Motley Fool

Roivant (ROIV) Q4 2025 Earnings Transcript ↗

May 20, 2026

Via The Motley Fool

Roivant Sciences Q4 Earnings Call Highlights ↗

May 20, 2026

Via MarketBeat

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 20, 2026

Via Chartmill

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

May 20, 2026

From Roivant Sciences

Via GlobeNewswire

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗

May 18, 2026

Via The Motley Fool

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗

May 18, 2026

Via The Motley Fool

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗

May 18, 2026

Via The Motley Fool

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

Via The Motley Fool

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

May 11, 2026

From Roivant Sciences

Via GlobeNewswire

Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones

April 02, 2026

Via MarketMinute

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

April 02, 2026

From Roivant Sciences

Via GlobeNewswire

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

April 02, 2026

From Roivant Sciences

Via GlobeNewswire

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

March 28, 2026

From Roivant Sciences

Via GlobeNewswire

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

Via The Motley Fool

Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement

March 05, 2026

Via MarketMinute

Frequently Asked Questions

Is Roivant Sciences Ltd. - Common Shares publicly traded?

Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.

What exchange does Roivant Sciences Ltd. - Common Shares trade on?

Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?

The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market

What is the current price of Roivant Sciences Ltd. - Common Shares?

The current price of Roivant Sciences Ltd. - Common Shares is 33.53

When was Roivant Sciences Ltd. - Common Shares last traded?

The last trade of Roivant Sciences Ltd. - Common Shares was at 09/02/26 11:29 AM ET

What is the market capitalization of Roivant Sciences Ltd. - Common Shares?

The market capitalization of Roivant Sciences Ltd. - Common Shares is 23.21B

How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?

Roivant Sciences Ltd. - Common Shares has 23B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.